FDA Proposes Bioequivalence Research On Inhalers, Other Complex Drugs
Executive Summary
FDA is recommending specific research projects that will help demonstrate the bioequivalence of generic versions of complex branded products
You may also be interested in...
Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel
Buyout of the private U.S. pharma company gives Sandoz a portfolio of generic drug candidates and technologies in asthma and COPD.
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.